Daniël Jan Ellens
Chairman of the Board – Chairman of the Nomination Committee
Daan J. Ellens (1948) has been member of the Board since 2005, and served as Chairman in 2007-2012, and Vice Chairman until April 2013. He is regarded as an independent board member.
Daan J. Ellens is Chairman of the Supervisory Board of Prosensa B.V. (The Netherlands), Hybrigenics SA (France) and Kreatech Holding B.V. (The Netherlands). Previously, he has held positions as CEO of Rhein Biotech N.V. (resigned December 2004), COO of Berna Biotech AG (resigned December 2004), CEO of Green Cross Vaccine Corporation Ltd (resigned December 2001), Member of the Supervisory Board of Life Sciences Partners (resigned May 2004), and as Venture Partner at Life Science Partners (resigned December 2012).
Daan J. Ellens holds a PhD in Molecular Biology from State University Utrecht in the Netherlands and an MBA from the University of Eindhoven, the Netherlands.
Vice Chairman of the Board
Jørgen Lindegaard (1948) has been member of the Board since 2011, and became Chairman in 2012 until April 2013. He is regarded as an independent board member.
Jørgen Lindegaard had more than 25 years of experience in the telecommunications industry, before he was appointed CEO of SAS in 2000. He left the company in 2006 to become the CEO of ISS A/S, from where he resigned in 2010. He serves as Chairman of the Board of AVT Business School A/S (Denmark), Scania (Denmark), Scania (Norway), JL Rungsted Holding (Denmark), Trifina Holding ApS (Denmark), K/S Vimmelskaftet 39-41 (Denmark) and of IT University of Copenhagen (Denmark).
Jørgen Lindegaard holds a M.Sc. Engineering (Electronics) from Technical University in Denmark.
Peter Benson (1955) has been member of the Board since 2007, and served as Vice Chairman 2010-2011. He is regarded as an independent board member.
Peter Benson is Managing Partner of Sunstone Capital and earlier was Partner and Head of Life Science Ventures from 2003. Prior to founding Sunstone Capital, he spent 20 years in the life science industry, including being President of Pharmacia Hospital Care. He also served on a number of Life Science boards, including the currently public listed companies Biogaia (Sweden), Ortivus (Sweden), Cellavision AB (Sweden) and Optovent AB (Sweden). Mr. Benson serves as a member of the Board of Asante Solutions Inc. (USA), Virogates A/S (Denmark), Alligator AB (Sweden) and Imix Holding AB (Sweden).
Peter Benson holds a Bachelor of Business Administration from the University of Lund and a M.A. in Economics from the University of California.
Board member, Chairman of the Clinical and Scientific Advisory Board
Alain Munoz (1949) has been member of the Board since 2005 (resigned in 2006, and re-elected in 2007), and is a non-independent member.
Alain Munoz is CEO and founder of Amistad Pharma S.A.S. (France) and Science, Business and Management SARL (France), and has over 20 years of experience in the pharmaceutical industry at senior management level. Within the Sanofi Group he served as SVP for International development (France) and in Fournier Laboratories as SVP for the Pharmaceutical division (France). He is a member of the Board of Valneva (France), Auris medical AG (Switzerland), Medesis Pharma SA (France) and Hybrigenics SA (France).
Alain Munoz holds an MD in Cardiology and Anaesthesiology from the Hospital Pitié-Salpétrière, Paris. He has numerous publications and has been a member of the scientific committee of the French Drug Agency.
Michael J. Owen
Michael J. Owen (1951) was elected to the Board of Zealand in 2012, and is regarded as an independent board member.
Michael J. Owen is a co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organisation and Fellowship of the Academy of Medical Sciences. He is a member of the Board of Ossianix, Inc. (USA) and BLINK Therapeutics (UK).
Michael J. Owen holds a PhD in amino acid transport in trypanosomes from Cambridge University, and a BA in Biochemistry from Keble College, Oxford University.
Board member and Chairman of the Remuneration Committee
Florian Reinaud (1973) has been member of the Board since 2010, and is regarded as an independent board member.
Florian Reinaud serves as Partner at CDC Innovation (France), and before joining CDC, he was the CFO of DBV Technologies (France). Prior to that, he worked at Apax Partners (France). Previously he was an equity analyst at Schroder Salomon Smith Barney (Citigroup) covering the pan-European medtech and healthcare services sectors. He also has worked as a doctor in the UK’s National Health Service (Accident & Emergency and Internal Medicine). He serves as a member of the Board of FAB Pharma SAS (France), Kuros Biosurgery AG (Switzerland), and as observer at the Board of Orthopaedic Synergy Inc. (USA).
Florian Reinaud holds a medical degree from Imperial College London and a BA (Hons) in Physiology from Oxford University.
Jens Peter Stenvang
Board member/employee elected
Jens Peter Stenvang (1954) has been member of the Board since 2014. Jens Peter holds a degree as laboratory technician in biology and has worked with cancer and diabetes research at leading universities including UC-Berkeley, California. Before joining Zealand in October 2010, Jens Peter worked for DAKO and Beckman Coulter as global Flow Cytometry support. Jens Peter has been member of the board of Dansk Selskab for Flowcytometri since 1990, excluding a short break from 2010-2012.
Board member/employee elected
Helle Størum (1967) has been member of the Board since 2008. Helle Størum is Business Development Manager at Zealand.
Helle Størum has more than 17 years of experience in the pharmaceutical industry, working with business development, market research, competitive Intelligence, forecasting and financial evaluations. She has previously been employed at Nycomed A/S and H. Lundbeck A/S. Helle Størum holds a M.Sc. (Economics) from University of Southern Denmark and a Diploma in Basic Pharmaceutical Medicine.
Board member/employee elected
Christian Thorkildsen (1968) has been member of the Board since 2005. Christian Thorkildsen is Project Director at Zealand. Mr. Thorkildsen holds an M.Sc. (Pharm) from the Danish University of Pharmaceutical Sciences.
Dr. Martin Nicklasson, (1955) joined Zealand’s Board of Directors as observer in 2014. It is the plan to present Martin for election as new independent, non-executive board member at Zealand’s Annual General Meeting in 2015. Martin has held various Executive Vice President positions at AstraZeneca Plc and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this he held a number of leadership positions at Astra and Kabi Pharmacia. Martin Nicklasson is chairman of the board of Orexo AB, Farma Holding and Basilea Pharmaceutica Ltd. He serves as a board member in Biocrine AB, PledPharma AB and Premier Research Group Ltd., and is also on the board of the Swedish Heart and Lung foundation. Martin is a certified pharmacist and holds a PhD in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.
Catherine Moukheibir joined Zealand’s Board of Directors as observer in 2014.Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy at various stages of a biotech’s development, and she is currently a non-executive Board member of Creabilis and Ablynx and a member of the management board at Innate Pharma. Catherine Moukheibir holds an MBA from Yale University.